2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 23:54, 18 December 2023
, 18 December 2023→3.1. Stilbenes: Resveratrol and Pterostilbene
| Line 297: | Line 297: | ||
===3.1. Stilbenes: Resveratrol and Pterostilbene=== | ===3.1. Stilbenes: Resveratrol and Pterostilbene=== | ||
Stilbenes, particularly resveratrol and pterostilbene, are non-flavonoid phenolic compounds extensively studied for their anti-inflammatory, antioxidant properties, and their role in combating age-related disorders like diabetes and cancer{{pmid|23448440}}{{doi|10.7324/JAPS.2019.90717|Chan EWC, Wong CW, Tan YH, Foo JPY, Wong SK, Chan HT. Resveratrol and pterostilbene: A comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties. J Appl Pharm Sci, 2019; 9(07):124–129.}}. They are found naturally in grapes and berries, and studies have established their safety and bioavailability, with doses of resveratrol up to 5 grams and pterostilbene to 250 mg being well-tolerated{{pmid|23431291}}{{pmid|30513922}}. | Stilbenes, particularly resveratrol and pterostilbene, are non-flavonoid phenolic compounds extensively studied for their anti-inflammatory, antioxidant properties, and their role in combating age-related disorders like diabetes and cancer{{pmid|23448440}}{{doi|doi=10.7324/JAPS.2019.90717|reftext=Chan EWC, Wong CW, Tan YH, Foo JPY, Wong SK, Chan HT. Resveratrol and pterostilbene: A comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties. J Appl Pharm Sci, 2019; 9(07):124–129.}}. They are found naturally in grapes and berries, and studies have established their safety and bioavailability, with doses of resveratrol up to 5 grams and pterostilbene to 250 mg being well-tolerated{{pmid|23431291}}{{pmid|30513922}}. | ||
Despite their potential, resveratrol and pterostilbene have shown lifespan extension only in certain preclinical models, with the results being context-dependent and subject to debate{{pmid|29210129}}. Pterostilbene is particularly notable for its higher bioavailability (80%) compared to resveratrol (20%), and its efficacy in upregulating antioxidant enzymes like SOD and GR{{pmid|23691264}}. This difference in bioavailability is critical in modulating the SIRT1 pathway, with co-administration of the two potentially maximizing their collective benefits{{pmid|18826454}}. | Despite their potential, resveratrol and pterostilbene have shown lifespan extension only in certain preclinical models, with the results being context-dependent and subject to debate{{pmid|29210129}}. Pterostilbene is particularly notable for its higher bioavailability (80%) compared to resveratrol (20%), and its efficacy in upregulating antioxidant enzymes like SOD and GR{{pmid|23691264}}. This difference in bioavailability is critical in modulating the SIRT1 pathway, with co-administration of the two potentially maximizing their collective benefits{{pmid|18826454}}. | ||
| Line 308: | Line 308: | ||
In summary, resveratrol and pterostilbene, especially when used in combination with NMN, represent a strategic orthomolecular approach to enhancing longevity and managing age-related diseases. | In summary, resveratrol and pterostilbene, especially when used in combination with NMN, represent a strategic orthomolecular approach to enhancing longevity and managing age-related diseases. | ||
==Clinical Trials== | ==Clinical Trials== | ||
Starting in 2020, with the assessment of the safety of a single dose administration of NMN, there have been around 10 randomized controlled trials (RCTs) exploring the compound's effects in various contexts. The trials have varied in duration, with the longest running for 12 weeks. In terms of dosage, they have explored a range of quantities, with the highest being 1,250 mg of NMN per day and 2,000 mg (2 g) of MIB-626, a specific formulation of NMN, per day. The following table provides a comprehensive overview of these trials, detailing their design, participant demographics, dosages, and key findings: | Starting in 2020, with the assessment of the safety of a single dose administration of NMN, there have been around 10 randomized controlled trials (RCTs) exploring the compound's effects in various contexts. The trials have varied in duration, with the longest running for 12 weeks. In terms of dosage, they have explored a range of quantities, with the highest being 1,250 mg of NMN per day and 2,000 mg (2 g) of MIB-626, a specific formulation of NMN, per day. The following table provides a comprehensive overview of these trials, detailing their design, participant demographics, dosages, and key findings: | ||